/

EMMA

Emmaus Life Sciences, Inc.Closed

0.0600+0.02 +40.19%USD

OTC Markets OTCQB · as of Oct 13, 16:00 ET · 15m delay

Open

0.0500

Prev close

0.0428

Day range

0.05000.0600

52-week range

0.0080000.0879

Volume

25.00K0.20×

Mkt cap

4.21M

P/E ttm

—

Fwd P/E

-0.86

EPS ttm

-0.0900

Div yield

0.00%

Earnings

—

From 52w high

−31.74%

Price Chart

Yahoo Finance · delayed

EMMAOct 13, 2026O 0.0500H 0.0600L 0.0500C 0.0600+0.0172 (+40.19%)Vol 47.00K

SMA 500.0462
SMA 2000.0206

1Y change +328.57% since Oct 13, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

EMMA Emmaus Life Sciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −0.40%
1 month: +16.28%
3 months: +423.56%
6 months: +545.16%
Year to date: +361.54%
1 year: +328.57%

Valuation & ownership

Market cap: 4.21M
Enterprise value: 31.81M
P/E (ttm): —
Forward P/E: -0.86
PEG ratio: —
Price / book: —
Price / sales (ttm): 0.27
EV / EBITDA: 6.90
EPS (ttm): -0.0900
EPS (forward): -0.0700
Beta (5y monthly): 9.77
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 70.19M
Float: 36.85M
Short % of float: 0.06%
Short ratio (days): 0.21
Held by insiders: 47.08%
Held by institutions: 0.00%
Avg volume (3m): 122.16K
50-day average: 0.0472
200-day average: 0.0209
52-week change: +328.57%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 53.0
vs 50-day SMA: +29.87%
vs 200-day SMA: +190.81%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 13.97%
Realised vol (20d, ann.): 285.9%
From 52-week high: −31.74%
From 52-week low: +650.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 15.53M
Revenue growth (yoy): +124.30%
Earnings growth (yoy): —
Gross margin: 93.60%
Operating margin: 60.00%
Profit margin: -38.78%

DES

About Emmaus Life Sciences, Inc.

Yahoo Finance profile

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 32
Headquarters: Torrance, CA, United States
Website: emmausmedical.com
Officers: Mr. Willis C. Lee M.S. CEO & Chairman of the Board
Ms. Hiroko Huynh CPA Chief Accounting Officer
Dr. Charles W. Stark Pharm.D. Chief Science Officer and EVP of Clinical Development & Medical Affairs
Mr. Dale E. Short J.D. Legal Consultant & Corporate Secretary

SEAS

Seasonality · EMMA

2007–2026 · monthly returns

Strongest month Sep +505.09%Weakest month Jul −18.30%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	6.9	0.7	7.1	-39.3	9.9	2.3	-2.2	499.0	9.3	-8.3			+361.5%
2025	91.8	7.4	-2.3	-3.5	20.6	-34.7	10.8	-24.3	0.9	-15.5	7.5	30.0	+52.9%
2024	29.9	-8.7	-11.5	-4.8	-8.0	9.9	-97.5	-88.0	9833.3	17.4	-14.6	-71.6	−91.5%
2023	53.6	-5.0	-20.4	4.1	1.6	-28.1	-4.3	-31.2	-17.4	-4.0	8.3	-23.0	−61.6%
2022	-16.2	3.6	-31.0	-20.0	-50.0	12.5	-22.2	2.9	-52.8	164.7	-13.8	-32.9	−84.4%
2021	5.7	8.5	21.3	-29.8	35.0	-12.3	5.6	3.3	3.2	-10.6	50.3	-22.3	+35.8%
2020	-38.1	31.1	-25.0	4.2	25.6	6.4	14.4	-21.5	-35.3	-18.0	44.6	7.0	−37.6%
2019	141.8	-12.4	-11.0	-9.4	-2.4	6.6	-16.5	-46.2	-31.4	22.9	-20.3	-16.2	−55.1%
2018	-4.7	-35.5	-43.1	75.6	24.9	-30.3	-20.3	30.3	-16.4	-11.1	-0.4	-47.7	−78.5%
2017	-0.6	-20.0	-18.1	4.2	-2.4	8.3	-41.4	-3.1	3.3	6.6	-11.1	-5.8	−62.4%
2016	-26.7	4.5	-13.0	5.0	-16.0	-3.6	29.4	0.0	36.4	46.7	0.6	2.3	+50.8%
2015	-6.5	-11.0	-6.4	-14.3	-30.0	-33.3	-7.1	-23.1	20.0	-16.7	-20.0	-25.0	−86.6%
2014	94.4	-7.1	4.6	-32.4	1.1	-24.7	-25.7	23.1	-29.7	-20.0	27.8	-2.4	−37.6%
2013	106.2	30.0	-30.8	42.2	59.4	-14.7	-70.7	-17.6	-28.6	66.7	0.0	-28.0	−25.8%
2012	-5.0	15.8	54.5	37.3	-40.0	-14.3	-66.7	-40.8	0.0	15.5	0.0	-40.9	−83.8%
2011	-45.0	90.9	0.0	11.9	-21.3	-29.7	3.8	-3.7	-3.8	-60.0	-5.0	5.3	−75.0%
2010	-13.3	5.8	109.1	-9.6	-8.7	0.0	-46.3	9.8	-10.7	10.0	-23.6	-4.8	−33.3%
2009	-1.1	-71.9	220.0	-13.8	-42.0	-55.0	11.1	200.0	-41.7	71.4	66.7	-40.0	−33.3%
2008	31.3	33.3	-27.9	-45.5	127.3	-44.0	0.0	-7.1	-21.5	98.0	0.0	-10.9	+12.5%
2007	-9.1	3900.0	400.0	12.5	-11.1	-37.5	-4.0	-25.0	-11.1	0.0	0.0	0.0	+7172.7%

EMMA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

EMMA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Emmaus Life Sciences, Inc.

Seasonality · EMMA

Insider Activity · EMMA

Congress Trades · EMMA

Investors Holding EMMA

Investors Holding EMMA

Congress Trades · EMMA

Insider Activity · EMMA

Seasonality · EMMA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Emmaus Life Sciences, Inc.

Earnings & Dividends

News